SCHEMBL12085040

SCHEMBL12085040

CC[C@H](NC)C(=O)N[C@@H](CC)C(=O)N[C@@H](CC)C(=O)N[C@@H](CC)C(=O)N[C@@H](CC)C(=O)N[C@@H](CC)C(=O)NCCOCCOCCOC

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ USP2 O75604 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ GLP1R P43220 8/20 0.34
▸ TLR2 O60603 5/20 0.34
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12082776 1.00 MEN1 (0.45) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL12085013 1.00 MEN1 (0.45) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL12084915 1.00 MEN1 (0.45) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL13625079 0.94 MEN1 (0.50) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL12085807 0.89 MEN1 (0.45) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL12085116 0.89 MEN1 (0.45) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL13158220 0.83 MEN1 (0.40) MEN1KMT2AUSP2TSHRGLP1R
SCHEMBL13157948 0.82 GNPAT (0.41) MEN1KMT2AGLP1RTLR2
SCHEMBL13010640 0.80 GLP1R (0.42) MEN1KMT2AGLP1RHPGD
SCHEMBL23177849 0.79 MEN1 (0.46) MEN1KMT2AUSP2TSHRTLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263665-B2 Polymeric micelles for drug delivery INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-11 — — US disclosed
US-8258190-B2 Encapsulated contrast agents INTEZYNE TECHNOLOGIES, INC. (US) 2012-09-04 — — US disclosed
US-20100159020-A1 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INC. (US) 2010-06-24 — — US disclosed
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides UNIVERSITY OF SOUTH FLORIDA (US) 2010-06-03 — — US disclosed
US-7638558-B2 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell INTEZYNE TECHNOLOGIES, INC. (US) 2009-12-29 — — US disclosed
US-7618944-B2 Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-17 — — US disclosed
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2009-04-09 — — US disclosed
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136063-A1 Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides IAPP, APP, TTR MEN1 271/4885KMT2A 3377/4885USP2 2488/4885
US-20080274965-A1 ENCAPSULATED AMYLOID-BETA PEPTIDES IAPP, APP, TTR MEN1 227/4885KMT2A 4844/4885USP2 1451/4885
US-20090092554-A1 ENCAPSULATED CONTRAST AGENTS LIPA, LPXN, CD47 MEN1 161/4885KMT2A 4044/4885USP2 1069/4885
US-20100159020-A1 POLYMERIC MICELLES FOR DRUG DELIVERY ABCB4, CLTB, CD47 MEN1 920/4885KMT2A 4479/4885USP2 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback